- Home
- DEC vs SVRA Comparison
DEC vs SVRA Comparison
Compare DEC & SVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DEC | SVRA |
|---|---|---|
| Founded | 2001 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.1B |
| IPO Year | 2022 | 2009 |
Fundamental Metrics
Financial Performance| Metric | DEC | SVRA |
|---|---|---|
| Price | $15.77 | $5.64 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 9 |
| Target Price | ★ $22.00 | $7.33 |
| AVG Volume (30 Days) | 1.2M | ★ 1.4M |
| Earning Date | 05-12-2026 | 05-12-2026 |
| Dividend Yield | ★ 7.46% | N/A |
| EPS Growth | ★ 311.06 | N/A |
| EPS | ★ 4.58 | N/A |
| Revenue | ★ $1,829,142,000.00 | N/A |
| Revenue This Year | $23.30 | N/A |
| Revenue Next Year | N/A | $430.87 |
| P/E Ratio | $3.39 | ★ N/A |
| Revenue Growth | ★ 141.54 | N/A |
| 52 Week Low | $11.21 | $1.89 |
| 52 Week High | $18.90 | $7.01 |
Technical Indicators
Market Signals| Indicator | DEC | SVRA |
|---|---|---|
| Relative Strength Index (RSI) | 47.55 | 51.47 |
| Support Level | $14.04 | $5.47 |
| Resistance Level | $16.09 | $6.10 |
| Average True Range (ATR) | 0.68 | 0.28 |
| MACD | -0.28 | 0.04 |
| Stochastic Oscillator | 7.52 | 57.55 |
Price Performance
Historical ComparisonAbout DEC Diversified Energy Company plc
Diversified Energy Co is an independent energy company focused on natural gas and liquids production, transportation, marketing and well retirement, located within the Appalachian and Central regions of the United States. Its principal focus is on enhancing producing wells, not drilling new wells, thereby allowing it to optimise PDP revenues and reduce costs. The company derives revenues from the sale of oil, natural gas and natural gas liquids.
About SVRA Savara Inc.
Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).